BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 15354212)

  • 1. Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line.
    To KF; Chan MW; Leung WK; Ng EK; Yu J; Bai AH; Lo AW; Chu SH; Tong JH; Lo KW; Sung JJ; Chan FK
    Br J Cancer; 2004 Oct; 91(7):1335-41. PubMed ID: 15354212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
    Lee TL; Yeh J; Van Waes C; Chen Z
    Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma.
    Niwa Y; Kanda H; Shikauchi Y; Saiura A; Matsubara K; Kitagawa T; Yamamoto J; Kubo T; Yoshikawa H
    Oncogene; 2005 Sep; 24(42):6406-17. PubMed ID: 16007195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma.
    Oshimo Y; Kuraoka K; Nakayama H; Kitadai Y; Yoshida K; Chayama K; Yasui W
    Int J Cancer; 2004 Dec; 112(6):1003-9. PubMed ID: 15386345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma.
    Galm O; Yoshikawa H; Esteller M; Osieka R; Herman JG
    Blood; 2003 Apr; 101(7):2784-8. PubMed ID: 12456503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
    Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
    Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity.
    Yoshikawa H; Matsubara K; Qian GS; Jackson P; Groopman JD; Manning JE; Harris CC; Herman JG
    Nat Genet; 2001 May; 28(1):29-35. PubMed ID: 11326271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition.
    Weber A; Hengge UR; Bardenheuer W; Tischoff I; Sommerer F; Markwarth A; Dietz A; Wittekind C; Tannapfel A
    Oncogene; 2005 Oct; 24(44):6699-708. PubMed ID: 16007169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative effect of SOCS-1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells.
    Souma Y; Nishida T; Serada S; Iwahori K; Takahashi T; Fujimoto M; Ripley B; Nakajima K; Miyazaki Y; Mori M; Doki Y; Sawa Y; Naka T
    Int J Cancer; 2012 Sep; 131(6):1287-96. PubMed ID: 22095154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer.
    He B; You L; Xu Z; Mazieres J; Lee AY; Jablons DM
    Clin Lung Cancer; 2004 May; 5(6):366-70. PubMed ID: 15217536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms.
    Fukushima N; Sato N; Sahin F; Su GH; Hruban RH; Goggins M
    Br J Cancer; 2003 Jul; 89(2):338-43. PubMed ID: 12865927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer.
    He B; You L; Uematsu K; Zang K; Xu Z; Lee AY; Costello JF; McCormick F; Jablons DM
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14133-8. PubMed ID: 14617776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway.
    Chim CS; Fung TK; Cheung WC; Liang R; Kwong YL
    Blood; 2004 Jun; 103(12):4630-5. PubMed ID: 14976049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling.
    Lejeune D; Demoulin JB; Renauld JC
    Biochem J; 2001 Jan; 353(Pt 1):109-116. PubMed ID: 11115404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells.
    Cheng J; Zhang D; Zhou C; Marasco WA
    Leuk Res; 2004 Jan; 28(1):71-82. PubMed ID: 14630083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome.
    Brakensiek K; Länger F; Schlegelberger B; Kreipe H; Lehmann U
    Br J Haematol; 2005 Jul; 130(2):209-17. PubMed ID: 16029449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells.
    Flowers LO; Subramaniam PS; Johnson HM
    Oncogene; 2005 Mar; 24(12):2114-20. PubMed ID: 15688010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis.
    Okochi O; Hibi K; Sakai M; Inoue S; Takeda S; Kaneko T; Nakao A
    Clin Cancer Res; 2003 Nov; 9(14):5295-8. PubMed ID: 14614012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling.
    van de Geijn GJ; Gits J; Touw IP
    J Leukoc Biol; 2004 Jul; 76(1):237-44. PubMed ID: 15107455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Janus kinase 2 by cisplatin in cancer cells.
    Song H; Sondak VK; Barber DL; Reid TJ; Lin J
    Int J Oncol; 2004 Apr; 24(4):1017-26. PubMed ID: 15010843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.